[Federal Register Volume 87, Number 140 (Friday, July 22, 2022)]
[Notices]
[Pages 43861-43862]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-15741]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


National Center for Health Statistics (NCHS), ICD-10 Coordination 
and Maintenance (C&M) Committee Meeting.

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The CDC, National Center for Health Statistics (NCHS), 
Classifications and Public Health Data Standards Staff, announces the 
following meeting of the ICD-10 Coordination and Maintenance (C&M) 
Committee. This meeting is open to the public, limited only by the 
number of audio lines available. Online registration is not required.

DATES: The meeting will be held on September 13, 2022, from 9 a.m. to 5 
p.m., EDT, and September 14, 2022, from 9 a.m. to 5 p.m., EDT.

ADDRESSES: This is a virtual meeting. Information will be provided on 
each of the respective web pages when it becomes available. For CDC, 
NCHS: https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For the 
Centers for Medicare & Medicaid Services (CMS), HHS: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.

FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Systems 
Specialist, CDC, NCHS, 3311 Toledo Road, Hyattsville, Maryland 20782-
2064; Telephone: (301) 458-4454; Email: [email protected].

SUPPLEMENTARY INFORMATION:
    Purpose: The ICD-10 Coordination and Maintenance Committee is a 
public forum for the presentation of proposed modifications to the 
International Classification of Diseases, Tenth Revision, Clinical 
Modification (CM) and ICD-10 Procedure Coding System (PCS).
    Matters To Be Considered: The tentative agenda will include 
discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda 
items are subject to change as priorities dictate. Please refer to the 
posted agenda for updates one month prior to the meeting.

[[Page 43862]]

ICD-10-PCS Topics

1. Administration of Lovotibeglogene autotemcel (lovo-cel) *
2. Administration of Exagamglogene autotemcel (exa-cel) **
3. External Support Device for AV Fistula Creation
4. Implantation of Polymethyl Methacrylate Cranioplasty Plates *
5. Insertion of Transcatheter Bicaval Valve System *
6. Implantation of Bioprosthetic Femoral Venous Valve
7. Intubated Prone Positioning
8. Section X Updates
9. Addenda and Key Updates

    * Requestor intends to submit a new technology add-on payment 
(NTAP) application for FY 2024.
    ** Request is for an April 1, 2023, implementation date, and the 
requestor intends to submit an NTAP application for FY 2024 
consideration.
    Presentations for procedure code requests are conducted by both the 
requestor and CMS during the C&M Committee meeting. Discussion from the 
requestor generally focuses on the clinical issues for the procedure or 
technology, followed by the proposed coding options from a CMS analyst. 
Topics presented may also include requests for new procedure codes that 
relate to a new technology add-on payment (NTAP) policy request.
    CMS is continuing to modify the approach for presenting the new 
NTAP-related ICD-10-PCS procedure code requests that involve the 
administration of a therapeutic agent for the September 13-14, 2022, 
ICD-10 Coordination and Maintenance Committee meeting. Consistent with 
the requirements of section 1886(d)(5)(K)(iii) of the Social Security 
Act, applicants submitted requests to create a unique procedure code to 
describe the administration of a therapeutic agent, such as the option 
to create a new code in Section X within the ICD-10-PCS procedure code 
classification. CMS will initially display only those meeting materials 
associated with the NTAP-related ICD-10-PCS procedure code requests 
that involve the administration of a therapeutic agent on the CMS 
website in early August 2022 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
    The two NTAP-related ICD-10-PCS procedure code requests that 
involve the administration of a therapeutic agent are:

1. Administration of Lovotibeglogene autotemcel (lovo-cel) *
2. Administration of Exagamglogene autotemcel (exa-cel) **

    These topics will not be presented during the September 13-14, 
2022, meeting. CMS will solicit public comments regarding any clinical 
questions or coding options included for these two procedure code 
topics in advance of the meeting continuing through the end of the 
respective public comment periods. Members of the public should send 
any questions or comments to the CMS mailbox at: 
[email protected].
    CMS intends to post a question-and-answer document in advance of 
the meeting to address any clinical or coding questions that members of 
the public may have submitted. Following the conclusion of the meeting, 
CMS will post an updated question-and-answer document to address any 
additional clinical or coding questions that members of the public may 
have submitted during the meeting that CMS was not able to address or 
that were submitted after the meeting.
    The NTAP-related ICD-10-PCS procedure code requests that do not 
involve the administration of a therapeutic agent and all non-NTAP-
related procedure code requests will continue to be presented during 
the virtual meeting on September 13, 2022, consistent with the standard 
meeting process.
    CMS will make all meeting materials and related documents available 
at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled 
for the September 13-14, 2022, ICD-10 Coordination and Maintenance 
Committee meeting that are under consideration for April 1, 2023, or 
October 1, 2023, implementation should be sent to the CMS mailbox at: 
[email protected].

ICD-10-CM Topics

1. Extraocular Muscle Entrapment
2. IGAN
3. Inappropriate Sinus Tachycardia
4. Insulin Resistance Syndrome
5. Leukodystrophies
6. Nontraumatic Coma Not Elsewhere Classified
7. Sickle Cell Retinopathy
8. Addenda

    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-15741 Filed 7-21-22; 8:45 am]
BILLING CODE 4163-18-P